The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) found that canakinumab at a dose of 150 mg every three months reduced adverse cardiovascular events in patients with previous myocardial infarction and C-reactive protein (CRP) levels of more than 2 mg/L [6]. Here, CRP is linked to myocardial infarction.